Table 2.

Adherence to treatment: effects of SGA LAIs on patient and caregiver needs, expectations, and personal experiences

Adherent patients		Partially adherent patients		Nonadherent patients
Personal experiences	Needs and expectations (toward illness and care)	Personal experiences	Needs and expectations (toward illness and care)	Personal experiences	Needs and expectations (toward illness and care)
- Burden of frequent visits to MHS -Constraints of taking pills in front of other (eg, patients with privacy concerns)	-Treatment deintensification -Flexible delivery of treatment - Fewer treatment-related SEs -Greater treatment satisfaction/better SWB	- Prior negative experience with AP treatments -Frequent disputes with caregivers about taking pills every day/ more than once a day	-More effective treatment - Need to be seen more often by MHS -No need to discuss nonadherence issues with clinicians -Fewer treatment-related SEs -Greater treatment satisfaction	-Complete lack of insight - Denial of illness - Traumatic experience with hospital admission and AP treatment (eg, high dose with significant sedative action) -Frequent disputes with caregivers about taking pills every day/ more once a day -Reluctance to see the physician	- Appropriate AP treatment -Greater treatment satisfaction/better SWB and QoL
Effects of SGA LAIs		Effects of SGA LAIs		Effects of SGA LAIs
More favorable pharmacokinetic and pharmacodynamic profile (better tolerability, SWB, treatment satisfaction, and QoL, lower risk of overtreatment, quaternary prevention) Reduction in treatment intensity (better hope and social acceptability, feeling of being on the road to recovery, greater involvement in life, no need of frequent visits) No need to take pills in front of others		More favorable pharmacokinetic and pharmacodynamic profile (better tolerability and SWB) Better clinical outcome (eg, relapse reduction, fewer positive symptoms) vs oral formulations Regular interactions between patient and MHS (reassurance of to receiving the best support possible) Less monitoring of treatment adherence (more time used to evaluate patient’s needs, greater empowerment) Reduction of disputes between patients and caregivers about taking medication		More favorable pharmacokinetic and pharmacodynamic profile (better tolerability and SWB) Guaranteed administration Earlier detection of possible relapses due to nonadherence, which can be followed up quickly Wider window of opportunity for caregivers to resume AP treatment, due to significant delay in time to relapse when treatment discontinued or withdrawn Reduction of disputes between patients and caregivers about taking medication

Abbreviations: AP, antipsychotic; MHS, mental health services; QoL, quality of life; SEs, side effects; SGA LAIs, second-generation long-acting injectable antipsychotics; SWB, subjective well-being.